TREATMENT OPTIONS FOR RECURRENT PLATINUM-SENSITIVE OVARIAN CANCER ARE EVOLVING

~80% of advanced ovarian cancers will RECUR during or after first-line treatment.

With watch and wait, median PFS was shown to decrease with each recurrence.

PLATINUM-FREE INTERVAL defines platinum sensitivity and may help predict response to subsequent chemotherapy.

For detailed recommendations (including recommended regimens for treatment of recurrent disease), see the complete version of the NCCN Guidelines for Ovarian Cancer.

References:
4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer V.2.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed January 18, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

For additional content on this topic, please visit www.GemstoneOncology.com